Clinical trials · Houston, TX
Hematologic Malignancy clinical trials in Houston
We’re tracking 31 recruiting hematologic malignancy studies with a site in or near Houston — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Houston
- NCT07195916RecruitingPhase 1
Testing a new drug for advanced solid tumors and blood cancers
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
Houston, TexasAges 18 years+ - NCT06034275RecruitingPhase 1
Study of VIP943 for CD123-positive blood cancers
This trial tests a new drug called VIP943 for people with advanced acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), or myelodysplastic syndrome (MDS) whose cancer cells have a marker called CD123. It is for those who have tried all other treatments or cannot receive them.
Houston, TexasAges 18 years+ - NCT04588922RecruitingPhase 1/Phase 2
Study drug SLS009 for high-risk leukemia in adults and teens
This early-phase study tests SLS009 (also called GFH009), a targeted medicine, to treat certain blood cancers—especially high-risk or difficult-to-treat AML. It’s designed to see how the drug works, how safe it is, and what dose may be best for you.
Houston, TexasAges 12 years+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Houston, TexasAges 6 months–25 years - NCT06807606RecruitingPhase 2
Cord blood transplant after relapse from first transplant
This trial tests a second transplant using two donated umbilical cord blood units for people whose blood cancer returned after a first stem cell transplant. It aims to offer a potential cure for high-risk blood cancers.
Houston, TexasAges Up to 60 years - NCT06001788RecruitingPhase 1
Ziftomenib for relapsed or refractory acute myeloid leukemia
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
Houston, TexasAges 18 years+ - NCT03802695RecruitingPhase 1
Orca-Q pill to help during stem cell transplant
This Phase 1 trial studies Orca-Q to see if it is safe and works when added around the time of an allogeneic (donor) stem cell transplant for certain blood cancers. If you qualify, the study may offer a new option for managing the transplant immune response.
Houston, TexasAges 12–78 - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
Houston, TexasAges 18 years+ - NCT05110742RecruitingPhase 1/Phase 2
CD5-targeting NK cell therapy for blood cancers
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT06208878Enrolling by invitation
Long-term follow-up for CRISPR CAR T therapy recipients
This study follows people who have already received a CRISPR CAR T cell therapy to monitor their long-term health and any side effects. It helps doctors understand how these treatments work over time.
Houston, TexasAges 18 years+ - NCT07572006RecruitingPhase 1
Study of JNJ-95804306 for blood cancers that returned or didn't respond
This trial tests a new drug called JNJ-95804306 for people with certain blood cancers (like acute myeloid leukemia, myelodysplastic syndromes, or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The goal is to see if the drug is safe and if it can help.
Houston, TexasAges 18 years+ - NCT06823167RecruitingPhase 1
Study of IM-1021 for advanced cancers
This trial tests a new drug (IM-1021) for people with advanced cancers like lymphoma or solid tumors who have run out of standard options. The drug targets a protein called ROR1, which is found on some cancer cells, and may help shrink tumors or slow their growth.
Houston, TexasAges 18 years+ - NCT06131801Recruiting
Crushed venetoclax tablet solution study for blood cancers
This study checks how the body handles venetoclax when it's given as a liquid made from crushed tablets. It's for children and young adults with blood cancers who already take venetoclax crushed or through a feeding tube.
Houston, TexasAges birth–38 years - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
Houston, TexasAges 18 years+ - NCT04888338Recruiting
Studying outcomes after CAR-T, radiation, or bispecific therapy
This study looks at how people with blood cancers do after they receive CAR-T therapy, radiation therapy, and/or bispecific therapy. It may help doctors understand which treatment combinations work best and what side effects to expect.
Houston, TexasAges 18 years+ - NCT05092451RecruitingPhase 1/Phase 2
CD70-targeting NK cell therapy for blood cancer relapse
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
Houston, TexasAges 12–80 - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Houston, TexasAges 18 years+ - NCT06950034RecruitingPhase 1
Testing STX-0712 for advanced CMML or AML
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT05041309Enrolling by invitation
Long-term follow-up after gene-modified cell treatment
This study is for people who have already received a special kind of cell therapy that involved modifying their genes. The purpose is to keep track of their health over a longer period of time to see how they are doing after the treatment.
Houston, TexasAges Any age - NCT05011045Recruiting
Brain radiation study tracking thinking and memory changes
This study looks at how whole-brain radiation affects thinking, memory, and other brain function in people with blood cancers that involve the brain. It may help doctors understand what to expect and which supportive treatments or monitoring could be useful.
Houston, TexasAges 18 years+ - NCT06938867RecruitingPhase 1/Phase 2
Study of SNIPR001 for stem cell transplant patients
This trial tests an oral treatment called SNIPR001 that targets a type of E. coli bacteria resistant to common antibiotics. It may help prevent infections during stem cell transplant recovery.
Houston, TexasAges 18 years+ - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Houston, TexasAges Any age - NCT03471260RecruitingPhase 1/Phase 2
Ivosidenib and venetoclax for IDH1-mutated leukemia or MDS
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Houston, TexasAges 18 years+ - NCT03486873RecruitingPhase 3
Study extension for people on pembrolizumab, testing long-term safety
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
Houston, TexasAges 18 years+
Hear when a new Hematologic Malignancy trial opens near Houston, TX
We’ll email you when one opens near Houston, TX — at most once a week, no account needed, unsubscribe anytime.
Hematologic Malignancy trials in other cities
Where these studies are running near Houston
Institutions with a site for the recruiting hematologic malignancy studies listed above.
- The University of Texas MD Anderson Cancer Center · 21 studies
- MD Anderson Cancer Center
- MD Anderson Cancer Center - University of Texas
- Texas Children's Hospital
- Texas Children's Hospital - Baylor Medical Center
What taking part in a hematologic malignancy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting hematologic malignancy studies in Texas.
Common questions
- Are there hematologic malignancy clinical trials near Houston?
- Yes. We're currently tracking 31 recruiting hematologic malignancy studies with a site near Houston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a hematologic malignancy study near Houston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Houston to take part?
- Not necessarily. These studies have a site near Houston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a hematologic malignancy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New hematologic malignancy studies open near Houston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.